
Astria Therapeutics (ATXS) Stock Forecast & Price Target
Astria Therapeutics (ATXS) Analyst Ratings
Bulls say
Astria Therapeutics Inc is positioned favorably in the biopharmaceutical landscape due to its promising product pipeline, particularly STAR-0215 and STAR-0310, which are addressing significant unmet needs in hereditary angioedema and atopic dermatitis, respectively. The preliminary data for STAR-0215 shows a remarkable 90-95% reduction in mean monthly attack rates, indicating strong efficacy and offering a unique prophylactic role that could enhance patient compliance through extended dosing. Additionally, STAR-0310 exhibits superior binding affinity and efficacy compared to existing treatments, showcasing its potential to lead in the market with differentiated therapeutic benefits.
Bears say
Astria Therapeutics's financial outlook appears negative due to several critical factors, including the risk of failed clinical trials and potential funding shortfalls that may inhibit the advancement of its drug candidates. The company's recent financial results for Q4 2024 showcased a larger-than-expected loss per share, with EPS reported at ($0.44) against estimates of ($0.50) and a consensus of ($0.45), indicating persistent challenges in meeting financial expectations. Additionally, competitive pressures and a modest efficacy/safety profile for its products compared to market leaders further exacerbate the risks associated with its stock performance.
This aggregate rating is based on analysts' research of Astria Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Astria Therapeutics (ATXS) Analyst Forecast & Price Prediction
Start investing in Astria Therapeutics (ATXS)
Order type
Buy in
Order amount
Est. shares
0 shares